Abstract: A communication method includes a first network device obtaining a first route and a second route from a second network device. A first network segment corresponding to the first route is a subnet segment of a second network segment corresponding to the second route. The second route is an aggregated route, and the first route indicates that the first network segment is unreachable. The first network device switches a next hop of the aggregated route based on the first route.

Abstract: A communication method includes a first network device obtaining a first route and a second route from a second network device. A first network segment corresponding to the first route is a subnet segment of a second network segment corresponding to the second route. The second route is an aggregated route, and the first route indicates that the first network segment is unreachable. The first network device switches a next hop of the aggregated route based on the first route.

Abstract: A bit index explicit replication (BIER) forwarding entry construction method is provided. The method includes receiving, by a second network device, a first message sent by a first network device, where the first message includes a host routing prefix of the first network device, first BIER information, and second BIER information. The first BIER information includes a bit index forwarding table identifier (BIFT ID) of the first network device, the second BIER information includes a bit forwarding router identifier (BFR ID) of at least one bit forwarding router (BFR) in a first area. The second network device constructs a BIER forwarding entry based on the first BIER information, the second BIER information, and the host routing prefix.

Abstract: A packet transmission method, a transmission control method, an apparatus, and a system are disclosed. A SR path includes a first network node and a second network node. There are a plurality of communication links between the first network node and the second network node. After obtaining a first packet, the first network node determines a first communication link based on a first link quality identifier carried in the first packet, and forwards the first packet to the second network node through the first communication link. The first link quality identifier indicates a first quality requirement on the communication link between the first network node and the second network node. The plurality of communication links between the first network node and the second network node include the first communication link, and link quality of the first communication link meets the first quality requirement.

Abstract: Described herein are compounds comprising a biologically active organic core group with one to five —Z—(X1—S(O)(X2)F)m groups attached thereto, wherein Z is O, NR, or N; X1 is a covalent bond or CH2CH2; m can be 1 or 2 depending on the identity of Z; and X2 is O or NR. In some embodiments, the core group is an amino acid or a protein. In some embodiments the core group is a compound that has therapeutic activity toward a therapeutic target.

Abstract: The present invention provides a high throughput method for constructing and screening a compound library and a reaction device. Specifically, the method of the present invention comprises: (a) providing a reactor comprising n independent and addressable reaction chambers; (b) performing m independent synthesis reactions in said n reaction chambers, thereby constructing a compound library; and (c) performing activity tests in reaction chambers in which synthesis reactions are performed. In the present invention, the preparation and screening processes of a compound can be completed in the same reaction system. As the reactions of the present invention almost quantitatively generate products, the products can be directly used in enzymatic or even cytological activity test experiments without separation.

Abstract: A communication method includes a first network device obtaining a first route and a second route from a second network device. A first network segment corresponding to the first route is a subnet segment of a second network segment corresponding to the second route. The second route is an aggregated route, and the first route indicates that the first network segment is unreachable. The first network device switches a next hop of the aggregated route based on the first route.

Abstract: A bit index explicit replication (BIER) forwarding entry construction method is provided. The method includes receiving, by a second network device, a first message sent by a first network device, where the first message includes a host routing prefix of the first network device, first BIER information, and second BIER information. The first BIER information includes a bit index forwarding table identifier (BIFT ID) of the first network device, the second BIER information includes a bit forwarding router identifier (BFR ID) of at least one bit forwarding router (BFR) in a first area. The second network device constructs a BIER forwarding entry based on the first BIER information, the second BIER information, and the host routing prefix.

Abstract: This application describes modified amino acids and polypeptides comprising a SO2F or CH2CH2SO2F group bound to the side chain of an amono acid or amino acid residue of a polypeptide in place of a hydrogen of a hydroxyl or amino substituent thereof. Methods of covalently binding the polypeptides to receptot sites of receptor proteins are also described herein.

Abstract: A 2D barcode encryption method, a 2D barcode transmission system and a storage medium are provided. The method includes: generating a first character string of a first numeral system based on information of a user; converting the first character string into a second character string of a second numeral system using a preset codebook, wherein the preset codebook is updated according to a first preset period, and a base number of the second numeral system is greater than that of the first numeral system; and generating a 2D barcode using the second character string. Security of access control for a shared space may be improved.

Abstract: This application describes a compound represented by Formula (I): wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.

Abstract: Disclosed in the present invention were a fluorosulfonyl-containing compound, an intermediate thereof, a preparation method therefor and use thereof. The fluorosulfonyl-containing compound disclosed in the present invention comprises a cation and an anion, the cation being as shown in Formula (1). The fluorosulfonyl-containing compound of the present invention can react with a substrate to efficiently synthesize a fluorosulfonylation product, has low toxicity, was simple to prepare, was convenient to use, and was in a solid stable state at normal temperature. Furthermore, the compound has a wide range of adaptable substrates, including phenolic compounds and amine compounds, and was the only solid form agent that can achieve such a chemical conversion, and therefore has important academic and application value.

Abstract: A compound for improving the gene editing specificity and application thereof. Specifically disclosed is a compound represented by formula I or a use of a pharmaceutically acceptable salt thereof. The compound and the pharmaceutically acceptable salt thereof are used for preparing an inhibitor, a composition, or a formulation for inhibiting gene editing and/or improving the gene editing specificity. The structure of the formula I is as stated in the description. The compound can significantly improve the accuracy of CRISPR gene editing, thereby providing a simple and high-efficient policy for accurate gene editing.

Abstract: Disclosed in the present invention were a fluorosulfonyl-containing compound, an intermediate thereof, a preparation method therefor and use thereof. The fluorosulfonyl-containing compound disclosed in the present invention comprises a cation and an anion, the cation being as shown in Formula (1). The fluorosulfonyl-containing compound of the present invention can react with a substrate to efficiently synthesize a fluorosulfonylation product, has low toxicity, was simple to prepare, was convenient to use, and was in a solid stable state at normal temperature. Furthermore, the compound has a wide range of adaptable substrates, including phenolic compounds and amine compounds, and was the only solid form agent that can achieve such a chemical conversion, and therefore has important academic and application value.

Abstract: This application describes a compound represented by Formula (I): wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.

Abstract: Disclosed in the present invention were a fluorosulfonyl-containing compound, an intermediate thereof, a preparation method therefor and use thereof. The fluorosulfonyl-containing compound disclosed in the present invention comprises a cation and an anion, the cation being as shown in Formula (1). The fluorosulfonyl-containing compound of the present invention can react with a substrate to efficiently synthesize a fluorosulfonylation product, has low toxicity, was simple to prepare, was convenient to use, and was in a solid stable state at normal temperature. Furthermore, the compound has a wide range of adaptable substrates, including phenolic compounds and amine compounds, and was the only solid form agent that can achieve such a chemical conversion, and therefore has important academic and application value.

Abstract: This application describes a compound represented by Formula (I): YZX1—S(O)(X2)F)m]n??(I) wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.

Abstract: Condensation of fluoro-substituted and silyl-substituted monomers provides polymers suitable for use, e.g., as engineering polymers. A monomer composition is condensed in the presence of a bifluoride or poly(hydrogen fluoride) fluoride salt. The monomer composition contains a compound of formula F-X-F and a compound of formula (R1)3Si—Z—Si(R1)3, and forms an alternating X-Z polymer chain and a silyl fluoride byproduct. X has the formula -A(-R2-A)n-; each A is SO2, C(?O), or Het; R2 is an organic moiety; n is 0 or 1; Het is an aromatic nitrogen heterocycle; Z has the formula -L-R3-L-; each L is O, S, or N(R4); and each R3 is an organic moiety, and R4 comprises H or an organic moiety.

Abstract: This application describes a compound represented by Formula (I): Y?Z?X1—S(O)(X2)F)m]n??(I) wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.

Abstract: This application describes a compound represented by Formula (I): (I) wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.